Herti 150 mg Injection – Trastuzumab 150 mg

Product Overview

Herti 150 mg Injection is an anti-cancer medicine containing Trastuzumab 150 mg, a targeted monoclonal antibody used in the treatment of certain HER2-positive cancers. It is prescribed by oncology specialists for eligible patients with specific types of breast cancer and other HER2-positive cancers.

Herti 150 mg works by targeting the HER2 protein, which may be present in unusually high amounts on certain cancer cells. By binding to this protein, Trastuzumab interferes with cancer-cell growth and helps the immune system recognise and attack these cells.

The medicine is generally used as part of a specialist-directed treatment plan. Before treatment, appropriate HER2 testing is required to determine whether the patient may benefit from Trastuzumab therapy.

Composition and Product Details

• Brand Name: Herti
• Salt Name: Trastuzumab
• Strength: 150 mg
• Dosage Form: Powder for Concentrate for Solution for Infusion
• Route of Administration: Intravenous infusion
• Manufacturer/Marketer: Hetero Healthcare Limited
• Packaging: 150 mg vial; confirm the exact pack contents and supplied diluent from the product carton.

Uses of Herti 150 mg Injection

Herti 150 mg may be prescribed for selected patients with HER2-positive cancers. Its use depends on the cancer type, disease stage, HER2 test results and the oncologist’s treatment plan.

1. HER2-Positive Breast Cancer

Trastuzumab is used in certain patients with HER2-positive early-stage or metastatic breast cancer. It may be prescribed alongside chemotherapy or other targeted medicines, depending on the clinical situation.

2. HER2-Positive Gastric Cancer

Trastuzumab may also be used in eligible patients with HER2-positive metastatic gastric or gastroesophageal junction cancer, generally in combination with other prescribed anti-cancer medicines.

Important: Not every breast or stomach cancer is HER2-positive. Appropriate laboratory testing is necessary before considering Trastuzumab treatment.

How Does Herti 150 mg Injection Work?

Herti 150 mg contains Trastuzumab, a humanised monoclonal antibody that specifically binds to the HER2 receptor on certain cancer cells.

HER2 is a protein that helps regulate cell growth and division. Some cancer cells produce excessive amounts of this protein, which can contribute to uncontrolled cell growth.

Trastuzumab attaches to the HER2 receptor and interferes with its growth-promoting activity. It can also activate immune-system mechanisms that help the body recognise and destroy HER2-positive cancer cells.

The response to treatment varies between patients. The oncology team evaluates treatment effectiveness through clinical assessments and appropriate investigations.

How Is Herti 150 mg Injection Administered?

Herti 150 mg is administered through an intravenous infusion by a qualified healthcare professional in an appropriate medical setting.

The prescribed amount and treatment schedule depend on several factors, including:

• Type and stage of cancer
• Patient’s body weight
• Treatment regimen
• Previous cancer treatments
• Overall health and response to therapy

The 150 mg vial represents the product’s strength, not necessarily the complete dose required by an individual patient. Some treatment regimens require more than one vial.

The medicine must be properly reconstituted and prepared before administration. Patients should never attempt to prepare or inject this medicine themselves.

Possible Side Effects

Like other prescription oncology medicines, Herti 150 mg may cause side effects. Their severity and frequency can vary between patients and may also depend on other medicines used in combination.

Commonly reported side effects may include:

• Fever and chills
• Nausea or vomiting
• Headache
• Diarrhoea
• Fatigue or weakness
• Skin rash
• Muscle or joint pain
• Infusion-related reactions
• Changes in blood-cell counts, particularly when combined with chemotherapy

Serious Side Effects

Trastuzumab can cause serious heart-related problems, including reduced heart function and heart failure. It may also cause severe infusion reactions, hypersensitivity reactions and lung-related complications.

Seek immediate medical attention if symptoms such as breathing difficulty, chest discomfort, severe dizziness, facial swelling or sudden worsening of health occur.

Important Precautions and Warnings

Heart Function Monitoring

Trastuzumab may affect heart function. Patients may require heart assessments before starting treatment and at regular intervals during therapy. Inform the oncologist about any existing heart condition or previous heart-related treatment.

Pregnancy and Breastfeeding

Trastuzumab may cause harm to an unborn baby. Patients who are pregnant, planning pregnancy or breastfeeding must discuss the risks with their oncologist before treatment.

Effective contraception and precautions after treatment should follow the approved prescribing information and medical advice.

Allergic Reactions

Inform the healthcare team about previous allergic reactions to Trastuzumab or any of the product’s ingredients.

Existing Medical Conditions

Patients should inform their oncologist about existing heart, lung or other medical conditions and all medicines currently being used.

Drug Interactions

Before starting Herti 150 mg, disclose all prescription medicines, over-the-counter products, supplements and previous cancer treatments to the treating oncologist.

Certain chemotherapy medicines, particularly anthracyclines, may increase the risk of heart-related complications when used in treatment plans involving Trastuzumab.

The oncology team will evaluate possible interactions and arrange appropriate monitoring. Do not start, stop or change any medicine without medical advice.

Storage and Handling

• Store the product according to the manufacturer’s instructions, generally under refrigerated conditions at 2°C–8°C.
• Protect the vial from light by keeping it in its original carton.
• Do not freeze the medicine.
• Follow the product-specific instructions for reconstitution and handling.
• Reconstituted and diluted solutions must be stored and used within the time limits specified in the approved product information.
• Preparation and disposal must be handled by trained healthcare professionals.

Always check the actual Herti 150 mg carton and package insert for exact storage conditions, diluent requirements and handling instructions.

Why Choose Speciality Drugs?

Speciality Drugs is a pharmaceutical distributor and exporter supporting pharmaceutical sourcing requirements across healthcare markets.

For Herti 150 mg enquiries, customers can contact Speciality Drugs for product availability, quotation requests and supply-related information.

• Pharmaceutical distribution and export support
• Product sourcing assistance
• Enquiry and quotation support
• Assistance for pharmacies, distributors and healthcare businesses

Contact Speciality Drugs for current availability and a product quotation.

Frequently Asked Questions (FAQs)

1. What is Herti 150 mg Injection?

Herti 150 mg is a prescription anti-cancer medicine containing Trastuzumab 150 mg, used for certain HER2-positive cancers.

2. What is the active ingredient in Herti 150 mg?

The active ingredient is Trastuzumab, a targeted monoclonal antibody that binds to the HER2 protein.

3. Who manufactures Herti 150 mg?

Herti 150 mg Injection is marketed by Hetero Healthcare Limited. Confirm the manufacturer and marketer details on the current product packaging.

4. What is Herti 150 mg used for?

It may be prescribed for eligible patients with certain HER2-positive breast cancers and other approved HER2-positive cancer indications.

5. Is HER2 testing required before treatment?

Yes. Appropriate HER2 testing is required to determine whether a patient’s cancer is suitable for Trastuzumab treatment.

6. How is Herti 150 mg Injection administered?

It is administered through an intravenous infusion by a qualified healthcare professional.

7. Is Herti 150 mg Injection a chemotherapy medicine?

Trastuzumab is a targeted monoclonal antibody therapy. It is different from conventional chemotherapy, although both may be used together in some treatment plans.

8. What are the common side effects?

Possible side effects include fever, chills, nausea, headache, diarrhoea, fatigue, skin rash and infusion-related reactions.

9. Can Herti 150 mg Injection affect the heart?

Yes. Trastuzumab may reduce heart function or cause heart failure in some patients. Regular medical monitoring is important.

10. Can Herti 150 mg be used during pregnancy?

Trastuzumab may harm an unborn baby. Pregnancy must be discussed with the treating oncologist before treatment.

11. Does Herti 150 mg Injection require refrigeration?

It is generally stored at 2°C–8°C. Always follow the storage instructions printed on the actual product packaging.

12. Can patients administer Herti 150 mg at home?

No. It requires professional preparation and intravenous administration in an appropriate medical setting.

13. Can Herti 150 mg Injection be used with other cancer medicines?

It may be combined with selected cancer medicines when prescribed by an oncologist. The combination depends on the cancer type and patient-specific treatment plan.

14. Is the 150 mg vial the complete dose for every patient?

No. The 150 mg strength refers to the amount of Trastuzumab in the vial. The oncologist determines the required dose according to the treatment regimen and patient-specific factors.

15. How can I enquire about Herti 150 mg Injection?

Contact Speciality Drugs for product availability, pricing and quotation-related enquiries.

Medical Disclaimer: This content is for general product information and educational purposes only. Herti 150 mg Injection is a prescription oncology medicine. Its use, dosage, preparation and monitoring must be determined by a qualified oncologist. This information does not replace professional medical advice.